Effects of angiotensin II and losartan in the forearm of patients with essential hypertension

Journal of Hypertension

Volumn 16, Issue 9, 1998, Pages 1299-1305

  Baan Jr , Jan ^a,b   Chang, Peter C ^a   Vermeij, Pieter ^a   Pfaffendorf, Martin ^b   Van Zwieten, Pieter A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin II; Forearm blood flow; Hypertension; Losartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; KIDNEY HORMONE; LOSARTAN; LOSARTAN POTASSIUM; METHOXAMINE; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASOCONSTRICTION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0031657266     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816090-00011     Document Type: Article

References (41)

1. Chang PC, Kriek E, van Brummelen P. Sympathetic activity and presynaptic adrenoceptor function in patients with longstanding essential hypertension. J Hypertens 1994; 12:179-190.
2. Van Zwieten P, Hendriks M, Pfaffendorf M, Bruning T, Chang P. The parasympathetic system and its muscarinic receptors in hypertensive disease. J Hypertens 1995; 13:1079-1090.
3. Alderman M, Madhaven S, Ooi W, Cohen H, Sealey J, Laragh J. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
4. Hayoz D, Nussberger J, Waeber B, Brunner HR, The renin-angiotensin system and arterial wall behaviour. J Cardiovsc Pharmacol 1993; 22:S48-S52.
5. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148-1154.
6. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94:1304-1309.
7. Schmieder RE, Weihprecht H, Schobel H, John S, Weidinger G, Gatzka C, Veelken R. Is endothelial function of the radial artery altered in human essential hypertension? Am J Hypertens 1997; 10:323-331.
8. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
9. Kelm M, Preik M, Hafner DJ, Strauer BE. Evidence for a multifactorial process involved in the impaired flow response to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension 1996; 27:346-353.
10. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349:837-842.
11. Bruning TA, Chang PC, Hendriks MG, Vermeij P, Pfaffendorf M, van Zwieten PA. In vivo characterization of muscarinic receptor subtypes that mediate vasodilatation in patients with essential hypertension. Hypertension 1995; 26:70-77.
12. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. W Engl J Med 1994; 330:1036-1040.
13. James MA, Watt PA, Potter JF, Thurston H, Swales JD. Endothelial function in subcutaneous resistance arteries from elderly hypertensive and normotensive subjects. Clin Sci 1997, 92:139-145.
14. Jie K, van Brummelen P, Vermeij P, Timmermans PBMWM, van Zwieten PA. Alpha 1-and alpha 2-adrenoceptor mediated vasoconstriction in the forearm of normotensive and hypertensive patients. J Cardiovasc Pharmacol 1986; 8:190-196.
15. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80:812-817.
16. Egan B, Schork N, Panis R, Hinderliter A. Vascular structure enhances regional resistance responses in mild essential hypertension. J Hypertens 1988; 6:41-48.
17. Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996; 14:263-270.
18. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13:1343-1351.
19. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
20. Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18:608-625.
21. Byyny RL, Merrill DD, Bradstreet TE, Sweet CS. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Cardiovasc Drugs Ther 1996, 10:313-319.
22. Baan J Jr, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Effects of losartan on vasoconstrictor responses to angiotensin II in the human forearm vascular bed of healthy volunteers. Cardiovasc Res 1996; 32:973-979.
23. Staessen JA, Bieniaszewski L, O'Brien ET, Fagard R. What is a normal blood pressure in ambulatory monitoring? [Special feature] Nephrol Dial Transplant 1996; 11:241-245.
24. Chang P, van Brummelen P. Calibration and variability of forearm blood flow, measured by strain-gauge plethysmography. J Cardiovasc Pharmacol 1987; 10:S123-S125.
25. Blauw GJ, van Brummelen P, Doorenbos CJ, van der Velde EA, van Zwieten PA. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or alpha 2-adrenergic receptors. Clin Pharmcol Ther 1991; 49:377-384.
26. 2-adrenoceptors in man. Circ Res 1984; 54:447-452.
27. Chang P, Grossman E, Kopin I, Goldstein D, Folio C, Holmes C. On the existence of functional angiotensin II receptors on vascular sympathetic nerve terminals in the human forearm. J Hypertens 1995; 13:1275-1284.
28. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb DJ. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918-923.
29. Preik M, Kelm M, Feelisch M, Strauer BE. Impaired effectiveness of nitric oxide-donors in resistance arteries of patients with arterial hypertension. J Hypertens 1996; 14:903-908.
30. Zhang J, Pfaffendorf M, Zhang JS, Van Zwieten PA. A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations Eur J Pharmacol 1994; 252:337-340.
31. Li Q, Feenstra M, Pfaffendorf M, Eijsman L, Van Zwieten P. Comparative vasoconstrictor effects of angiotensin II, angiotensin III and angiotensin IV in human isolated saphenous vein. J Cardiovasc Pharmacol 1997; 29:451-456.
32. Li Q, Zhang J, Pfaffendorf M, Van Zwieten P. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol 1995; 116:2963-2970.
33. Zhang JS, Van Meel JC, Pfaffendorf M, Van Zwieten PA. Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein. Naunyn Schmiedebergs Arch Pharmacol 1993; 347:220-224.
34. Okunishi H, Song K, Oka Y, Kobayashi T, Kawamoto T, Ishihara H, et al. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177. Jpn J Ptomacol 1993; 62:239-244.
35. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35:290-297.
36. Sweet CS, Bradstreet DC, Bergman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7:1035-1040.
37. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP 753 - an orally antihypertensive agent. J Pharmacol Exp Ther 1990; 255:211-217.
38. Folkow B. Hypertensive structural changes in systemic precapillary resistance vessels: how important are they for in vivo haemodynamics? J Hypertens 1995; 13:1546-1559.
39. Vanhoutte P. Endothelial dysfunction in hypertension. J Hypertens 1996; 14 (suppl):S83-S93.
40. Agabiti-Rosei E, Muiesan ML, Muiesan G. Regression of structural alterations in hypertension. Am J Hypertens 1989; 2:70S-76S.
41. Agabiti-Rosei E, Muiesan ML, Geri A, Romanelli G, Montani G, Muiesan G. Relation between cardiac hypertrophy and forearm vascular structural changes before and during long-term antihypertensive treatment. Am J Med 1988; 84:125-128.